First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies

Sarina A. Piha-Paul*, Kyaw Z. Thein, Paul De Souza, Richard Kefford, Tara Gangadhar, Christopher Smith, Shelly Schuster, William C. Zamboni, Claire E. Dees, Ben Markman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background This was a phase I/IIa study to investigate the tolerability, efficacy and pharmacokinetics (PK)/ pharmacodynamics (PD) of CRLX301, CDP-based nanoparticle formulation of docetaxel. Methods The study was conducted in two parts. In part 1, dose-escalation using a standard 3 + 3 design was performed in two dosing schedules (every week (QW) and every 3 weeks (Q3W)). Part 2 was comprised of a dose expansion at 75 mg/m2 Q3W. PK studies were performed on both dosing schedules. Results Forty-two patients were recruited onto the study with a median age of 64(range 38–76); median number of prior systemic therapies was 5(range 0–10). Grade 3/4 treatment-related toxicities included: neutropenia (21.4 %), infusion related reaction (11.9 %), anemia (7.1 %), fatigue (4.8 %), diarrhea (4.8 %), and peripheral neuropathy (4.8 %). The maximum tolerated dose was 75 mg/m2 given on the Q3W schedule and was not determined on the QW schedule. In this heavily pre-treated population, four patients (12.9 %) achieved stable disease (SD) ≥ 4 months and 2 patients (6.5 %) achieved partial response (PR) for a clinical benefit rate (CBR) of 19.4 % (6/31 patients). The PRs were seen in prostate and breast adenocarcinoma (one each). CRLX301 exhibited some PK advantages over docetaxel including higher retention of drug in plasma, slower clearance and controlled slow release of docetaxel from the carrier. Conclusions In this heavily pretreated patient population, the safety profile was acceptable for CRLX301 therapy. There was some evidence of preliminary tumor efficacy, but further work is necessary to find the optimal dose and schedule of this formulation. Clinicaltrials.gov trial registration number: NCT02380677 (Date of registration: March 2, 2015).

Original languageEnglish
Number of pages10
JournalInvestigational New Drugs
Early online date16 Feb 2021
DOIs
Publication statusE-pub ahead of print - 16 Feb 2021

Keywords

  • CRLX301
  • Docetaxel
  • First‐in‐human study
  • Nanoparticle
  • Phase I/IIa study

Fingerprint Dive into the research topics of 'First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies'. Together they form a unique fingerprint.

Cite this